FDA approves daraxonrasib, doubling survival time in pancreatic cancer trial

The US Food and Drug Administration has approved the pill daraxonrasib for pancreatic cancer treatment. In a pivotal clinical trial, patients who received the drug lived twice as long as those who underwent chemotherapy. Experts say the approval could transform the treatment of one of the deadliest and hardest-to-treat cancers.